BiomarkersReview
Plasma p ‐tau changes across the clinical spectrum of Alzheimer's disease: a systematic review and meta‐analysis
AAIC 2025 Abstract
Abstract
Background: Alzheimer's disease (AD) plasma biomarkers have transformed the field due to their scalability and minimal invasiveness, especially when evidence of AD biomarker abnormality is required for novel anti‐amyloid immunotherapies.
The paper
Wagner Scheeren Brum, Joseph Therriault, Arthur C. Macedo, Pedro Rosa‐Neto
Show 17 more authors
Lydia Trudel, Fernando Bittemcourt, Martin Nakouzi, Ilaria Pola, Matthew Wong, Przemysław Radosław Kac, Ana Paula Bernardes Real, Chloë Witherow, Thomas K. Karikari, Alexis Moscoso, Michael Schöll, Andrea Lessa Benedet, Tharick Ali Pascoal, Nicholas James Ashton, Eduardo Rigon Zimmer, Henrik Zetterberg, Kaj Blennow,Universidade Federal do Rio Grande do Sul · McGill University
AAIC 2025 Abstract · 8 Jan 2026 · CC BY
Presented at AAIC 2025
